| Budget Amount *help |
¥192,140,000 (Direct Cost: ¥147,800,000、Indirect Cost: ¥44,340,000)
Fiscal Year 2022: ¥37,700,000 (Direct Cost: ¥29,000,000、Indirect Cost: ¥8,700,000)
Fiscal Year 2021: ¥37,700,000 (Direct Cost: ¥29,000,000、Indirect Cost: ¥8,700,000)
Fiscal Year 2020: ¥37,700,000 (Direct Cost: ¥29,000,000、Indirect Cost: ¥8,700,000)
Fiscal Year 2019: ¥37,700,000 (Direct Cost: ¥29,000,000、Indirect Cost: ¥8,700,000)
Fiscal Year 2018: ¥41,340,000 (Direct Cost: ¥31,800,000、Indirect Cost: ¥9,540,000)
|
|---|
| Outline of Final Research Achievements |
To elucidate the regulatory mechanisms of immune and inflammatory cell activation and differentiation by regulatory molecules controlling neuroimmunometabolism, we found that LRRK2, the gene responsible for Parkinson's disease, a neurodegenerative disease, and its analog LRRK1 are responsible for the physiological activity of semaphorins through the regulation of activation of the small G protein Rab7. We found that LRRK2, a gene responsible for Parkinson's disease, and its analog LRRK1 are responsible for the physiological activity of semaphorins via regulating the activation of small G protein Rab7. Regarding the analysis of intracellular metabolic changes involved in immune and inflammatory cell differentiation, we found that activation of intracellular lipid metabolism via the mTOR-Sema6D-PPARγ pathway is essential during inhibitory macrophage differentiation and suppresses the development of enteritis.
|
| Assessment Rating |
Ex-post Assessment Comments (Rating)
A: In light of the aim of introducing the research area into the research categories, expected outcomes of research have been produced.
|
Assessment Rating |
Interim Assessment Comments (Rating)
A: In light of the aim of introducing the research area into the research categories, the expected progress has been made in research.
|
